{"id":"arq-151-cream-0-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Application site burning"},{"rate":null,"effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL4303449","moleculeType":"Small molecule","molecularWeight":"552.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PDE4 inhibition increases intracellular cAMP levels in immune and inflammatory cells, suppressing the production of pro-inflammatory cytokines such as TNF-α and IL-23. This mechanism reduces skin inflammation and is particularly effective in atopic dermatitis and other inflammatory skin conditions where PDE4 plays a key pathogenic role.","oneSentence":"ARQ-151 is a topical phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in skin.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:30.169Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis"},{"name":"Plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT04286607","phase":"PHASE3","title":"Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2020-02-12","conditions":"Chronic Plaque Psoriasis","enrollment":333},{"nctId":"NCT04655313","phase":"PHASE2","title":"Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2020-11-30","conditions":"Psoriasis, Plaque Psoriasis","enrollment":20},{"nctId":"NCT04746911","phase":"PHASE2","title":"Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-03-01","conditions":"Psoriasis, Plaque Psoriasis","enrollment":10},{"nctId":"NCT04211363","phase":"PHASE3","title":"Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-12-20","conditions":"Chronic Plaque Psoriasis","enrollment":439},{"nctId":"NCT04211389","phase":"PHASE3","title":"Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-12-17","conditions":"Chronic Plaque Psoriasis","enrollment":442},{"nctId":"NCT03638258","phase":"PHASE2","title":"The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2018-09-21","conditions":"Plaque Psoriasis","enrollment":331},{"nctId":"NCT03764475","phase":"PHASE2","title":"Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2018-12-18","conditions":"Plaque Psoriasis","enrollment":332},{"nctId":"NCT04279119","phase":"PHASE1","title":"Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2020-03-10","conditions":"Plaque Psoriasis","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Topical roflumilast"],"phase":"phase_3","status":"active","brandName":"ARQ-151 cream 0.3%","genericName":"ARQ-151 cream 0.3%","companyName":"Arcutis Biotherapeutics, Inc.","companyId":"arcutis-biotherapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ARQ-151 is a topical phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in skin. Used for Atopic dermatitis, Plaque psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}